• Home
  • YLS Today
  • Events
  • YLS Corporate Law and Solomon Health Law Centers' Craig Wasserman '86/Wachtell, Lipton, Rosen & Katz Alumni Breakfast
November 8 Thursday

YLS Corporate Law and Solomon Health Law Centers' Craig Wasserman '86/Wachtell, Lipton, Rosen & Katz Alumni Breakfast

  • Thursday, November 8, 2018 at 7:30AM - 9:20AM
  • The Century Association, 7 W 43rd St, New York, NY 10036
  • Open To The YLS Community Only
  • Event URL
  • Add to Calendar:


The Yale Law School Center for the Study of Corporate Law and the Solomon Center for Health Law and Policy at Yale Law School are delighted to invite you to attend a special Craig Wasserman '86/Wachtell, Lipton, Rosen & Katz Alumni Breakfast program in New York. On Thursday, November 8, 2018, the two centers are jointly hosting a breakfast program on “Innovative Approaches to the Challenge of Pharmaceutical R&D: Financing, Investing, and Innovation.” The program will be held at The Century Association, 7 West 43rd Street (between 5th and 6th Avenues), from 8:00—9:20 a.m.

The pharmaceutical industry has seen decreases in R&D productivity despite innovations in biomedical research; what models are needed to finance and incentivize the R&D required to translate innovation into treatments? Pablo Legoretta, CEO of Royalty Pharma, Vivek Ramaswamy '13, CEO of Roivant Sciences, Richard Thakor, Ph.D./M.S./M.Sc., Assistant Professor at University of Minnesota Carlson School of Management, and Janet Woodcock, M.D., Director of the Food and Drug Administration’s Center for Drug Evaluation and Research will discuss these issues. Yale Law School Professor Abbe R. Gluck ’00, Faculty Director of the Solomon Center, will moderate. Among the topics to be discussed are the special economic challenges that pharma R&D faces; the panelists’ own personal successful experience with innovative financing mechanisms in this area and why those new financing mechanisms emerged; what new financing mechanisms may be on the horizon; whether the pharmaceutical industry, like other industries, could use a specialized lender; whether there are regulations or practices that could be eliminated to spur greater investment; the role insurance reimbursement plays; the extent to which the FDA as well as public and private insurers should consider the effect of their decisions on the capital market for financing innovation; and what the financial and pharmaceutical sectors themselves could do better to improve the system and the market.

Register here

Sponsoring Organization(s)

Alumni & Development

Contact Information

Alumni and Development Office